Jowell Global Ltd. Announces Cooperative Partnership with Leading European Pharmaceutical Company STADA to Promote Its Zoflora Disinfectants Portfolio in China
13 Ottobre 2022 - 2:00PM
Jowell Global Ltd. (“JWEL” or the “Company”) (NASDAQ: JWEL), one of
the leading cosmetics, health and nutritional supplements, and
household products e-commerce platforms in China, today announced
that it has entered into a cooperative partnership with STADA to
promote its Zoflora disinfectant products in China. Under the terms
of the cooperation agreement, STADA licensed Jowell as its
exclusive distributor to sell its Zoflora products on Jowell’s
e-commerce platform to accelerate its outreach in the cleaning and
consumer products market in China.
As the fourth-largest consumer healthcare
products company in Europe, STADA offers consumers, pharmacists and
retail partners a broad and rapidly growing portfolio of strong
local brands across multiple therapeutic categories. Its
disinfectant brand Zoflora is a home hygiene product with a
century-old heritage and reputation in the United Kingdom. In
recent years, capitalizing on digital distribution channels and the
growing local demand, Zoflora has been actively deployed into the
Chinese market.
Fan Zhou, General Manager of STADA Shanghai,
Greater China, commented: “This collaboration combines the
advantages of both parties, and we are confident in the greater
synergies that STADA and Jowell will create to meet the demand of
the massive disinfectants market in China. As one of China’s
leading e-commerce platforms for household products, cosmetics,
health and nutrition supplements, Jowell Global is a proven partner
in providing STADA with one of the largest new retail and ecommerce
platforms for household and consumer products, as well as extensive
sales resources, distribution channels and better support in the
new retail realm in China.”
Mr. Zhiwei Xu, Chief Executive Officer and
Chairman of Jowell Global Ltd, stated: “We are thrilled to have
Zoflora products available to our customers. STADA is a
leading manufacturer of high-quality pharmaceuticals with a
long-standing heritage rooted in pharmacies, and is perceived as a
reliable and trustworthy partner for more than 125 years. With
continuous outbreak of COVID-19, increased awareness of health,
demand for safe and effective sanitary and cleaning products to
contain the spread of COVID-19, we are confident that STADA’s
disinfectant products will be well received by consumers in China.
This strategic cooperation will be a win-win for both parties in
bringing our communities together and in further providing our
customers with high-quality and innovative products. This is also a
positive milestone in showcasing our accelerating efforts in
introducing new brands and products to our customers. Moving
forward, we will continue collaborating with top global brands and
companies via our robust sales network in order to achieve our goal
of becoming one of the world’s largest new retail enterprises.”
About Jowell Global Ltd.
Jowell Global Ltd. (the “Company”) is one of the
leading cosmetics, health and nutritional supplements and household
products e-commerce platforms in China. The Company offers its own
brand products to customers; also sells and distributes health and
nutritional supplements, cosmetic products and certain household
products from other companies on its platform. In addition, the
Company allows third parties to open their own stores on its
platform for a service fee based upon sale revenues generated from
their online stores. The Company provides them with its unique and
valuable information about market needs, enabling them to better
manage their sales effort, as well as an effective platform to
promote their brands. In addition, the Company sells its products
through authorized retail stores all across China, which operates
under the brand names of “Love Home Store” or “LHH Store” and
“Juhao Best Choice Store”. For more information, please visit
http://ir.1juhao.com/
About STADA Arzneimittel
AG
STADA Arzneimittel AG is headquartered in Bad
Vilbel, Germany. STADA focuses on a three-pillar strategy
consisting of generics, specialty pharma and non-prescription
consumer healthcare products. STADA Arzneimittel AG sells its
products in approximately 120 countries worldwide. In financial
year 2021, STADA achieved group sales of EUR 3,249.5 million and
reported earnings before interest, taxes, depreciation and
amortization (EBITDA) of EUR 776.5 million. As of 31 December 2021,
STADA employed 12,520 people worldwide. For more information,
please visit https://www.stada.com/
Safe Harbor Statement
This press release contains forward-looking
statements. These statements are made under the "safe harbor"
provisions of the U.S. Private Securities Litigation Reform Act of
1995. Statements that are not historical facts, including
statements about the Company's beliefs and expectations, are
forward-looking statements. Forward-looking statements involve
inherent risks and uncertainties, and a number of factors could
cause actual results to differ materially from those contained in
any forward-looking statement. In some cases, forward-looking
statements can be identified by words or phrases such as "may,"
"will," "expect," "anticipate," "target," "aim," "estimate,"
"intend," "plan," "believe," "potential," "continue," "is/are
likely to" or other similar expressions. The Company may also make
written or oral forward-looking statements in its reports filed
with, or furnished to, the U.S. Securities and Exchange Commission,
in its annual reports to shareholders, in press releases and other
written materials and in oral statements made by its officers,
directors or employees to third parties. These statements are
subject to uncertainties and risks including, but not limited to,
the following: the Company’s goals and strategies; the Company’s
future business development; financial condition and results of
operations; product and service demand and acceptance; reputation
and brand; the impact of competition and pricing; changes in
technology; government regulations; fluctuations in general
economic and business conditions in China and assumptions
underlying or related to any of the foregoing and other risks
contained in reports filed by the Company with the SEC. For these
reasons, among others, investors are cautioned not to place undue
reliance upon any forward-looking statements in this press release.
Additional factors are discussed in the Company’s filings with the
SEC, which are available for review at www.sec.gov. The Company
undertakes no obligation to publicly revise these forward‐looking
statements to reflect events or circumstances that arise after the
date hereof.For investor and media inquiries, please contact:
Jowell Global Ltd.Ms. Jessie ZhaoEmail: IR@1juhao.com
Seaquant Consulting Mr. Roye ZhangEmail: roye@sea-quant.com
- Cooperation Between Jowell Global & STADA
Grafico Azioni Jowell Global (NASDAQ:JWEL)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Jowell Global (NASDAQ:JWEL)
Storico
Da Gen 2024 a Gen 2025